| Unique ID issued by UMIN | UMIN000057246 |
|---|---|
| Receipt number | R000065434 |
| Scientific Title | Development of a method for early and minimally invasive diagnosis, severity assessment, and treatment response evaluation of cardiac amyloidosis using a hybrid amyloid imaging method combining 18F-Flutemetamol-PET and 99mTc-HMDP scintigraphy |
| Date of disclosure of the study information | 2025/03/10 |
| Last modified on | 2025/03/09 17:38:26 |
Development of a method for early and minimally invasive diagnosis, severity assessment, and treatment response evaluation of cardiac amyloidosis using a hybrid amyloid imaging method combining 18F-Flutemetamol-PET and 99mTc-HMDP scintigraphy
Cardiac amyloidosis research using Vizamyl and Clearborn
Development of a method for early and minimally invasive diagnosis, severity assessment, and treatment response evaluation of cardiac amyloidosis using a hybrid amyloid imaging method combining 18F-Flutemetamol-PET and 99mTc-HMDP scintigraphy
Cardiac amyloidosis research using Vizamyl and Clearborn
| Japan |
Amyloidosis
| Medicine in general |
Others
NO
We will evaluate the usefulness of hybrid amyloid imaging combining 99mTc-HMDP scintigraphy and 18F-Flutemetamol-PET in early minimally invasive diagnosis, severity assessment, and treatment response assessment of cardiac amyloidosis. As a secondary evaluation, we will also evaluate the ability of these two imaging methods to detect amyloid deposits in organs other than the heart.
Efficacy
The intensity and pattern of cardiac accumulation of two types of tracers (99mTc-HMDP and 18F-Flutemetamol), the relationship between the intensity and clinical parameters, and the time course of the accumulation if positive.
Detectability of amyloid deposits in organs other than the heart using two imaging methods
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Diagnosis
| Other |
18F-Flutemetamol-PET and 99mTc-HMDP scintigraphy
| 18 | years-old | <= |
| 100 | years-old | > |
Male and Female
1.Patients aged 18 years or older who have been definitively diagnosed with amyloidosis
2.Patients who are able to express their will and have voluntarily agreed to participate in the study, or patients who are unable to express their will and have their proxy consent to participate in the study
1.Patients with a history of allergies to the study drug
2.Other subjects who the principal investigator deems inappropriate to be subjects
100
| 1st name | Yoshiki |
| Middle name | |
| Last name | Sekijima |
Shinshu University School of Medicine
Department of Medicine (Neurology and Rheumatology)
390-8621
Asahi 3-1-1, Matsumoto, Nagano
0263-37-2673
sannai@shinshu-u.ac.jp
| 1st name | Nagaaki |
| Middle name | |
| Last name | Katoh |
Shinshu University School of Medicine
Department of Medicine (Neurology and Rheumatology)
390-8621
Asahi 3-1-1, Matsumoto, Nagano
0263-37-2673
nagaaki@shinshu-u.ac.jp
Shinshu University
Ministry of Education, Culture, Sports, Science and Technology
Japanese Governmental office
Nihon Medi-Physics Co., Ltd.
Life Science and Medical Research Ethics Committee, Shinshu University School of Medicine
Asahi 3-1-1, Matsumoto, Nagano, Japan
0263-37-2572
mdrinri@shinshu-u.ac.jp
NO
| 2025 | Year | 03 | Month | 10 | Day |
Unpublished
Open public recruiting
| 2024 | Year | 10 | Month | 28 | Day |
| 2024 | Year | 12 | Month | 03 | Day |
| 2025 | Year | 02 | Month | 19 | Day |
| 2028 | Year | 12 | Month | 31 | Day |
| 2025 | Year | 03 | Month | 09 | Day |
| 2025 | Year | 03 | Month | 09 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000065434